Evotec, Triton Partners
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal
Germany-based Evotec SE (NASDAQ:EVO) is trading on Monday after a report that suggests the company is a takeover target. The private equity firm Triton Partners is reportedly considering acquiring Evotec,
Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. The merger aims to enhance ...
News of the offer arrived days after Bloomberg reported that the private equity group Triton Partners, which has built ...
MT Newswires on MSN9h
Halozyme Submits $2.11 Billion Acquisition Offer For EvotecHalozyme Therapeutics (HALO) offered to acquire German drug maker Evotec (EVO) in a deal with an equity value of 2 billion euros ($2.11 billion). Halozyme submitted a non-binding proposal to Evotec's ...
Evotec surged on Friday after Halozyme Therapeutics confirmed it had submitted a non-binding proposal to buy the German ...
Evotec’s struggles have put it in the crosshairs of private equity groups. After seeing the company’s share price fall around ...
Triton Partners is considering a takeover bid for Germany’s Evotec SE, according to people familiar with the matter, after the private equity firm emerged as one of the drug developer’s ...
23h
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to ...
Halozyme Therapeutics Inc. (HALO) confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of ...
Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback